A novel variant of SARS-CoV-2, B.1.1.7,originally discovered in the UK, is rapidly overtaking wild-type SARS-CoV-2 globally, 1 due to a substantial transmission advantage.This variant is estimated to be 40% to 80% more transmissible 2 and 35% more lethal 3 than the wild-type virus.Deletion of amino acids 69 and 70 within the spike (S) gene of SARS-CoV-2 B.1.1.7,sometimes attributable to the N501Y mutation, can result in an undetectable S-gene target (S-gene target failure, SGTF) for some real-time reverse transcriptase polymerase chain reaction (RT-PCR) testing methods.A rapid increase in the proportion of SARS-CoV-2 samples with SGTF was identified in regions of England affected by B.1.1.7,and, after validation with whole genome sequencing, SGTF was determined to be a reliable marker of B.1.1.7 across the country. 2 To quantify the spread of B.1.1.7 in the Greater Toronto Area, we tracked SGTF prevalence between December 2020 and March 2021.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: